ELI-002

Vaccine demonstrates benefit in delaying cancer relapse

10 January 2024 | By Catherine Eckford (European Pharmaceutical Review)

Data from the Phase I trial showed that the cancer vaccine offered an 86 percent reduction in the risk of relapse or death in pancreatic and colorectal cancers.